Brickell biotech, inc. (VICL)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-

-

-12,960

-8,973

-

-

-

-

-

-

-

Net Income (Loss) Attributable to Parent

-23,900

-9,236

-

-

-9,238

-16,492

-31,238

-22,899

-7,283

-30,385

-28,558

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

28

49

-

-

-

-

-

-

-

-

-

Accretion of discount on marketable securities

41

0

-

-

-

-

-

-

-

-

-

Non-cash interest expense

666

0

-

-

-

-

-

-

-

-

-

Impairment expense

400

0

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liability

-11

0

-

-

-

-

-

-

-

-

-

Fair Value Adjustment of Warrants

-223

-244

-

-

-

-

-

-

-

-

-

Change in fair value of contingent consideration

-145

-3

-

-

-

-

-

-

-

-

-

Gain on extinguishment

2,318

0

-

-

-

-

-

-

-

-

-

Amortization of discounts and financing costs

1,575

489

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

793

1,117

1,159

1,663

2,213

2,328

2,507

2,808

2,629

Accretion of discount on short-term investments

-

-

0

0

-

-

-

-

-

-

-

Write-off of abandoned patents

-

-

0

374

230

350

889

71

-

-

-

Gain on sale of property and equipment

-

-

0

0

1

15

7

9

-

-

5

Other than temporary loss on marketable securities and other assets

-

-

-

-

-

-

-

-

-

-

405

Write-off of abandoned patents

-

-

-

-

-

-

-

-

-

148

86

Stock-based compensation

1,532

711

756

990

1,902

3,159

3,466

-

3,106

-

-

Write-off of abandoned patents and licensed technology

-

-

-

-

-

-

-

-

75

-

-

Compensation expense related to stock options and awards

-

-

-

-

-

-

-

3,290

-

-

-

Purchase of technology license with common stock

-

-

-

-

775

0

0

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

4,562

115

-

-

-

-

-

-

-

-

-

Accounts payable

-1,822

2,845

-

-

-

-

-

-

-

-

-

Accrued liabilities

671

-241

-

-

-

-

-

-

-

-

-

Deferred contract costs

-

-

4,989

5,428

-817

-

-

-

-

-

-

Receivables and other assets

-

-

1,973

-840

995

-412

2,626

-

-

-

-

Receivables and other assets

-

-

-

-

-

-

-

-977

-

-

-

Compensation expense related to stock options and awards

-

-

-

-

-

-

-

-

-

2,636

1,385

Receivables and other assets

-

-

-

-

-

-

-

-

1,923

-409

-503

Accounts payable and accrued expenses

-

-

1,313

557

-1,415

1,635

-2,188

-792

-51

-1,771

1,848

Deferred revenue

-7,917

9,712

8,682

2,768

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

250

-150

0

51

99

-1,990

281

Deferred rent

-

-

223

633

432

368

307

247

169

83

26

Net Cash Provided by (Used in) Operating Activities

-36,000

3,967

-8,601

-8,388

-

-

-

-

-3,639

-28,228

-21,452

CASH FLOWS FROM INVESTING ACTIVITIES:
Cash and cash equivalents acquired in recapitalization

13,017

0

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-6,948

-9,806

-29,798

-17,230

-

-

-

Proceeds from the sale of marketable securities

-

-

-

-

-

-

-

3,750

-

-

-

Maturities of marketable securities

19,500

0

31,429

30,652

20,183

10,556

30,974

22,151

-

-

-

Capital expenditures

7

12

-

-

-

-

-

-

-

-

-

Purchases of marketable securities

-

-

36,640

38,069

-

-

-

-

-

-

-

Purchases of marketable securities

-

-

-

-

20,050

22,643

5,137

51,842

-

-

-

Sale of property and equipment

-

-

0

0

3

15

49

9

-

-

10

Maturities of marketable securities

-

-

-

-

-

-

-

-

20,220

31,815

16,018

Purchases of marketable securities

-

-

-

-

-

-

-

-

24,598

18,549

24,657

Purchases of property and equipment

-

-

80

255

72

85

332

646

256

347

337

Net cash provided by (used in) investing activities

32,510

-12

-5,291

-7,672

-

-

-

-

-5,040

12,506

-9,281

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the exercise of stock options

0

45

-

-

-

-

-

-

-

-

-

Patent and licensed technology expenditures

-

-

-

-

53

269

412

409

406

413

315

Net cash (used in) provided by investing activities

-

-

-

-

11

-12,426

25,142

-26,987

-

-

-

Net proceeds from issuance of common stock and pre-funded warrants

-

-

30,549

7,758

3

-

-

-

-

-

-

Proceeds from the issuance of common stock and warrants, net of offering cost

-

-

-

-

-

3,925

816

48,933

214

37,261

33,038

Proceeds from the exercise of warrants

47

0

-

-

-

-

-

-

-

-

-

Payments of Debt Issuance Costs

0

50

-

-

-

-

-

-

-

-

-

Proceeds from issuance of convertible promissory notes

7,397

0

-

-

-

-

-

-

-

-

-

Payments of principal of note payable

4,808

1,282

-

-

-

-

-

-

-

-

-

Principal payments under equipment financing obligations

-

-

-

-

-

-

-

-

-

-

156

Payment of withholding taxes for net settlement of restricted stock units

-

-

4

14

23

59

482

253

159

92

37

Net cash provided by financing activities

2,636

-1,287

30,545

7,744

-

-

-

-

55

37,169

32,845

NET DECREASE IN CASH AND CASH EQUIVALENTS

-835

2,668

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-20

3,866

334

48,680

-

-

-

Net decrease in cash, cash equivalents and restricted cash

-

-

16,653

-8,316

-6,957

-

-

-

-

-

-

Supplement Disclosure of Cash Flow Information:
Gain related to deferred rent

-

-

0

0

-

-

-

-

-

-

-

Net decrease in cash and cash equivalents

-

-

-

-

-

-18,366

-4,322

4,463

-8,624

21,447

2,112

Interest paid

432

608

-

-

-

-

-

-

-

0

2

Supplement Disclosure of Non-Cash Investing and Financing Activities:
Conversion of redeemable convertible preferred stock and preferred stock dividends to common stock

48,016

0

-

-

-

-

-

-

-

-

-

Reduction of redeemable convertible preferred stock to redemption value

-10,377

5,896

-

-

-

-

-

-

-

-

-

Shares issued in recapitalization

23,076

0

-

-

-

-

-

-

-

-

-

Warrants to purchase common stock issued with convertible promissory notes

8,063

0

-

-

-

-

-

-

-

-

-

Accretion of redeemable convertible preferred stock issuance costs

103

40

-

-

-

-

-

-

-

-

-

Derivative liability issued with convertible promissory notes

1,442

0

-

-

-

-

-

-

-

-

-

Warrants to purchase common stock issued with funding agreement

876

0

-

-

-

-

-

-

-

-

-

Warrants to purchase common stock issued with convertible promissory notes

1,492

0

-

-

-

-

-

-

-

-

-

Change in unrealized loss on available-for-sale marketable securities

-28

0

-

-

-

-

-

-

-

-

-